Shire Uses Foresight To Expand In Ophthalmology
This article was originally published in The Pink Sheet Daily
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.
You may also be interested in...
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.